MX2017006551A - Terapias de envenenamiento y composiciones farmaceuticas, sistemas y equipos relacionados. - Google Patents

Terapias de envenenamiento y composiciones farmaceuticas, sistemas y equipos relacionados.

Info

Publication number
MX2017006551A
MX2017006551A MX2017006551A MX2017006551A MX2017006551A MX 2017006551 A MX2017006551 A MX 2017006551A MX 2017006551 A MX2017006551 A MX 2017006551A MX 2017006551 A MX2017006551 A MX 2017006551A MX 2017006551 A MX2017006551 A MX 2017006551A
Authority
MX
Mexico
Prior art keywords
poisoning
inhibitor
antiserum
systems
pharmaceutical compositions
Prior art date
Application number
MX2017006551A
Other languages
English (en)
Other versions
MX387186B (es
Inventor
R Lewin Matthew
Original Assignee
Ophirex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ophirex Inc filed Critical Ophirex Inc
Publication of MX2017006551A publication Critical patent/MX2017006551A/es
Publication of MX387186B publication Critical patent/MX387186B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención proporciona métodos de tratamiento, composiciones farmacéuticas, sistemas y equipos apropiados para la terapia de primera línea y/o complementaria con un antisuero, que utiliza al menos un componente activo, en algunos casos, al menos dos componentes activos y en otros casos, no más de dos componentes activos, seleccionados del grupo que consiste de un inhibidor de PLA2 secretor selectivo (inhibidor de sPLA2 o PLA2), un inhibidor de metaloproteinasa, un inhibidor de serina proteasa, antisuero, uno o más inhibidores de acetilcolinesterasa o un agonista de nAChR apareado con un antagonista de rnAChR, un antagonista del receptor de NMDA y un inhibidor del factor de propagación para tratar a un sujeto que sufre de un envenenamiento, de manera preferida, al momento del envenenamiento y con frecuencia, en el transcurso de un periodo de menos de aproximadamente una hora después de un envenenamiento o 6 horas después de un envenenamiento y durante el curso de tratamiento al momento, con o sin un antisuero como una terapia complementaria, después del envenenamiento por, por ejemplo, una serpiente o invertebrado.
MX2017006551A 2014-11-21 2015-11-20 Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados. MX387186B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462082895P 2014-11-21 2014-11-21
US201562131441P 2015-03-11 2015-03-11
US201562243374P 2015-10-19 2015-10-19
PCT/US2015/061834 WO2016081826A2 (en) 2014-11-21 2015-11-20 Envenomation therapies and related pharmaceutical compositions, systems and kits

Publications (2)

Publication Number Publication Date
MX2017006551A true MX2017006551A (es) 2018-01-15
MX387186B MX387186B (es) 2025-03-18

Family

ID=56014685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006551A MX387186B (es) 2014-11-21 2015-11-20 Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados.

Country Status (18)

Country Link
US (2) US11000506B2 (es)
EP (1) EP3220902A4 (es)
JP (1) JP6883515B2 (es)
KR (2) KR20170086089A (es)
CN (1) CN107249578B (es)
AU (1) AU2015349774B2 (es)
BR (1) BR112017010495B1 (es)
CA (1) CA2968383C (es)
CR (1) CR20170259A (es)
EA (1) EA037262B1 (es)
IL (1) IL252418B (es)
MA (1) MA40998A (es)
MX (1) MX387186B (es)
MY (1) MY187053A (es)
PH (1) PH12017500927A1 (es)
SG (1) SG11201704106VA (es)
TW (1) TWI745280B (es)
WO (1) WO2016081826A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10786483B2 (en) * 2016-03-04 2020-09-29 Hk Pharma Tumescent contravenom drug delivery
CA3022013C (en) 2016-04-29 2025-08-12 Ophirex, Inc. Secreted pla2 inhibitors for immediate treatment of hymenoptera envenomation
WO2018112313A1 (en) * 2016-12-16 2018-06-21 The Regents Of The University Of California Neutralizing venomous biomacromolecules
US10961276B2 (en) * 2017-02-17 2021-03-30 CAMRIS International, Inc. Universal antivenom
CN108703975A (zh) * 2018-08-30 2018-10-26 黄汝怡 一种治疗毒虫叮咬的涂抹剂
CN109260196A (zh) * 2018-11-08 2019-01-25 中国科学院海洋研究所 巴马司他作为制备水母皮炎药物的应用
EP4045026A4 (en) * 2019-10-15 2023-11-08 Ophirex, Inc. Early management and prevention of sepsis and sepsis-like syndromes
US12564575B2 (en) 2019-10-15 2026-03-03 Ophirex, Inc Early management, mitigation and prevention of sepsis and sepsis-like syndromes, including neo-natal ARDS due to infection, injury or iatrogenesis
CN112494498A (zh) * 2020-12-11 2021-03-16 中国人民解放军海军军医大学 四环素在制备预防或缓解水母蜇伤药物中的应用
WO2022216953A1 (en) * 2021-04-08 2022-10-13 Believe In A Cure, Inc. Compounds for use in increasing foxg1 expression
US12285408B2 (en) * 2021-05-14 2025-04-29 Liverpool School Of Tropical Medicine Methods and compositions for the treatment of snake bite
KR102726781B1 (ko) * 2021-06-22 2024-11-06 전남대학교산학협력단 한국형 살무사과 사독의 항사독 조성물
CN113817738B (zh) * 2021-10-20 2023-06-16 湖南科技学院 银杏长链非编码rna及其在银杏内酯生物合成中的应用
US20240382452A1 (en) * 2021-11-09 2024-11-21 Ophirex, Inc. Compositions and dosage forms for topical and transdermal delivery of actives and methods of use
EP4487851A4 (en) 2022-03-04 2026-01-07 Korea Inst Radiological & Medical Sciences PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATMENT OF SKIN DISEASES CAUSED BY RADIATION, COMPRISING DARAPLADIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS THE ACTIVE INGREDIENT
CN117462543A (zh) * 2023-11-02 2024-01-30 南昌大学 一种蛇毒治疗组合物及应用
WO2026002883A1 (de) 2024-06-24 2026-01-02 Alexander Ruebben Kombinationspräparat umfassend varespladib und einen dimercapto-chelatbildner zur behandlung und/oder prophylaxe von schlangenbissen

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196193A (en) 1989-10-31 1993-03-23 Ophidian Pharmaceuticals, Inc. Antivenoms and methods for making antivenoms
BR9501404A (pt) * 1994-04-01 1996-03-05 Lilly Co Eli 1H-indol-3 glioxilamida e formulação farmacèutica
AUPP076797A0 (en) 1997-12-05 1998-01-08 Active (Pla) R&D Pty Ltd Phospholipase inhibitor
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
RU2349315C9 (ru) 2003-04-14 2010-02-27 Лтс Ломанн Терапи-Системе Аг Терапевтический пластырь с полисилоксановой матрицей, содержащей капсаицин
JP2007505870A (ja) 2003-09-19 2007-03-15 イギリス国 有機リン酸中毒の治療用の医薬組成物
EP1684753A2 (en) 2003-10-28 2006-08-02 Cornell Research Foundation, Inc. Neuromuscular blocking agents and antagonists thereof
US20070026079A1 (en) 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
JP5221355B2 (ja) 2005-10-12 2013-06-26 アドバンスト・アクセレレーター・アプリケーションズ・エスアー 治療及び診断用途のための選択的αｖβ３レセプターペプチドアンタゴニスト
EP2069377A4 (en) 2006-09-27 2009-11-11 Univ California METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
US20090062369A1 (en) * 2007-08-31 2009-03-05 Joaquim Trias Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
WO2009047762A1 (en) 2007-10-09 2009-04-16 Yeda Research And Development Co. Ltd Compositions and peptides for treatment of envenomation by pla2 containing venoms like bungarus multicinct venom
CN110522905A (zh) 2008-01-21 2019-12-03 德莫迪斯公司 丝氨酸蛋白酶抑制剂在治疗皮肤病中的用途
CA2751884C (en) 2009-01-14 2018-09-25 Corium International, Inc. Transdermal administration of tamsulosin
WO2011049979A2 (en) 2009-10-19 2011-04-28 Amira Pharmaceuticals, Inc. Injectable formulations for intra- articular or peri-articular administration
US20130253060A1 (en) * 2011-09-21 2013-09-26 Harihara M. Mehendale Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS)
US9795773B2 (en) 2011-12-16 2017-10-24 Indosys Limited Medicament unit dose cartridge and delivery device
AU2013312240A1 (en) 2012-09-10 2015-03-19 Ophirex Inc. Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
US20140087003A1 (en) * 2012-09-21 2014-03-27 Ignacio Cisneros Method for treating venomous bites and stings

Also Published As

Publication number Publication date
MY187053A (en) 2021-08-27
WO2016081826A3 (en) 2016-07-14
WO2016081826A2 (en) 2016-05-26
US20170354642A1 (en) 2017-12-14
BR112017010495B1 (pt) 2023-12-05
EA037262B1 (ru) 2021-03-01
IL252418B (en) 2021-01-31
CR20170259A (es) 2017-10-02
JP2017536372A (ja) 2017-12-07
MX387186B (es) 2025-03-18
KR102885213B1 (ko) 2025-11-14
AU2015349774A1 (en) 2017-06-01
EP3220902A4 (en) 2018-11-07
CN107249578B (zh) 2021-01-26
JP6883515B2 (ja) 2021-06-09
US12274691B2 (en) 2025-04-15
MA40998A (fr) 2017-09-26
KR20170086089A (ko) 2017-07-25
TWI745280B (zh) 2021-11-11
SG11201704106VA (en) 2017-06-29
TW201632204A (zh) 2016-09-16
CA2968383A1 (en) 2016-05-26
IL252418A0 (en) 2017-07-31
EP3220902A2 (en) 2017-09-27
AU2015349774B2 (en) 2020-07-02
EA201791122A1 (ru) 2018-04-30
BR112017010495A2 (pt) 2018-04-03
CA2968383C (en) 2024-03-12
US20210260029A1 (en) 2021-08-26
KR20240117660A (ko) 2024-08-01
PH12017500927A1 (en) 2017-11-20
CN107249578A (zh) 2017-10-13
US11000506B2 (en) 2021-05-11

Similar Documents

Publication Publication Date Title
MX2017006551A (es) Terapias de envenenamiento y composiciones farmaceuticas, sistemas y equipos relacionados.
EA201691516A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201791243A1 (ru) Лечение пузырчатки
EA201890325A1 (ru) Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний
PH12017500583A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201891132A1 (ru) Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
AR086582A1 (es) Anticuerpos anti-kir para el tratamiento de trastornos inflamatorios y autoinmunes
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2015012867A (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
MX389699B (es) Composiciones que comprenden anticuerpos inhibidores de masp-2 para usarse en el tratamiento de post-trasplante de celulas madre de microangiopatía trombótica (tma).
EA201691368A1 (ru) ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ
MX383930B (es) Compuestos de pirazol sustituidos como inhibidores de serina proteasa.
MX2015009276A (es) Donadores de nitroxilo con indice terapeutico mejorado.
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
UY35687A (es) Inhibidores de rorc2 y sus métodos de uso
MX394452B (es) Inhibicion de la actividad de olig2.
BR112017007916A2 (pt) compostos sarms para tratamento de distúrbios urológicos
ZA201901367B (en) Inhibition of olig2 activity
BR112016024749A2 (pt) composto, composição farmacêutica, e, método de tratamento de câncer, de um distúrbio inflamatório, de um distúrbio de autoimunidade ou de um distúrbio neurodegenerativo
EA201591480A1 (ru) Способы лечения дискинезии и сопутствующих расстройств